I received the following clarification from Omer Shvili this morning, who spoke to Pharmos managing director Michael Schickler in Israel:
<<Just like I thought, he said that the lady from Globes misunderstood him. When he said 3-4 years, he meant the time it would take to get approval and start selling the product. They will submit an NDA much sooner than that.>>
Omer is very knowledgeable about the company and considered the GLOBES piece valuable even with the misunderstanding. Now all we have to do is keep our fingers crossed that the BOL partnership is going to begin to pay off this year.
That happening, plus announcements of how the company finishes Phase II for HU-211 and gives details on plans for Phase III ought to move the stock.
And, hopefully, this GLOBES misunderstanding, the NIH article, and the soft current stock price will indicate to PARS management that we need a higher PR profile. If we do need to raise equity again, we'll need much fewer shares if the stock price is more robust and that will mean less dilution for us, including PARS management.
Happy Trading,
Ariella |
